Search Patents
-
Patent number: 7452542Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.Type: GrantFiled: May 23, 2005Date of Patent: November 18, 2008Assignee: Vanderbilt UniversityInventor: Mark Denison
-
Patent number: 10434168Abstract: The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.Type: GrantFiled: September 2, 2015Date of Patent: October 8, 2019Assignee: Intervet Inc.Inventors: Catherine M. Peters, Mark W. Mellencamp, Wenzhi Xue, Terri Wasmoen, Emilio Trigo
-
Patent number: 11911462Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.Type: GrantFiled: July 12, 2023Date of Patent: February 27, 2024Assignee: INSTITUT PASTEURInventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
-
Patent number: 10130701Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.Type: GrantFiled: July 23, 2015Date of Patent: November 20, 2018Assignee: THE PIRBRIGHT INSTITUTEInventors: Erica Bickerton, Sarah Keep, Paul Britton
-
Patent number: 6974577Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: February 4, 2001Date of Patent: December 13, 2005Assignee: Novartris AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Patent number: 7309493Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: August 1, 2005Date of Patent: December 18, 2007Assignee: Novartis AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Patent number: 11524071Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a coronavirus vaccine adjuvant.Type: GrantFiled: October 15, 2020Date of Patent: December 13, 2022Assignee: 3M Innovative Properties CompanyInventor: Paul D. Wightman
-
Patent number: 11684667Abstract: Coronaviruses, vaccines comprising the same, and methods for preventing disease. One embodiment of such includes a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a non-structural protein (nsp)-15, the replicase gene encoding the nsp15 and causes any change, including mutations and/or deletions, that affects the stability or activity of the nsp15.Type: GrantFiled: March 2, 2018Date of Patent: June 27, 2023Assignee: LOYOLA UNIVERSITY OF CHICAGOInventors: Susan Baker, Xufang Deng
-
Publication number: 20100266628Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.Type: ApplicationFiled: April 13, 2010Publication date: October 21, 2010Inventors: Majid Razzak, Robert Holmes
-
Patent number: 7618802Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.Type: GrantFiled: January 19, 2006Date of Patent: November 17, 2009Assignee: The University of North Carolina at Chapel HillInventors: Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis
-
Patent number: 8313752Abstract: An injectable composition, capable of preventing or controlling parasitic, viral, or bacterial infections or diseases, for example scours, in pregnant cows and viral infections or diseases in neonatal calves by parenterally administering to each cow in a herd of pregnant cows, a dose of a combination composition comprising: (a) at least one inactivated viral component derived from rotavirus and/or coronavirus; (b) a macrocyclic lactone active compound; and (c) a pharmaceutically acceptable parenteral carrier and preservative. The injectable compositions which include eprinomectin result in extremely low milk residues.Type: GrantFiled: April 13, 2010Date of Patent: November 20, 2012Assignee: Merial LimitedInventors: Majid Razzak, Robert Holmes
-
Patent number: 7556957Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product.Type: GrantFiled: November 14, 2003Date of Patent: July 7, 2009Assignees: Stichting voor de Technische Wetenschappen, Universiteit UtrechtInventors: Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Bert Jan Haijema
-
Publication number: 20080081047Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.Type: ApplicationFiled: December 6, 2004Publication date: April 3, 2008Inventors: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer
-
Patent number: 8541003Abstract: SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen.Type: GrantFiled: June 21, 2004Date of Patent: September 24, 2013Assignee: Protein Sciences CorporationInventors: D. Karl Anderson, Kathleen M. Holtz-Corris, Rick Chubet, Daniel Adams, Manon Cox
-
Publication number: 20080069839Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.Type: ApplicationFiled: May 24, 2004Publication date: March 20, 2008Inventors: Yi Guan, Bo-Jiang Zheng